We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Consensus and Guidelines · January 20, 2021

Nivolumab + Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naïve Metastatic ccRCC

European Urology

 

Additional Info

European Urology
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab Plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-Naïve Metastatic Clear-Cell Renal Cell Carcinoma
Eur Urol 2020 Dec 20;[EPub Ahead of Print], J Bedke, L Albiges, U Capitanio, RH Giles, M Hora, TB Lam, B Ljungberg, L Marconi, T Klatte, A Volpe, Y Abu-Ghanem, S Dabestani, SF Pello, F Hofmann, T Kuusk, R Tahbaz, T Powles, A Bex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading